+44 (0) 115 787 0500

Research & Candidate Selection

Expert advice and support for early-stage discovery programs seeking new treatments for drug addiction, psychiatric and neurological disorders, obesity and binge-eating disorder. All aspects of strategy, screening and project support management are performed with a strong focus on clinical success and regulatory approval.

Our services include:

  • Design of innovative non-clinical studies, preparation of experimental protocols, outsourcing and monitoring projects, the analysis and interpretation of data, and preparation of regulatory-standard reports
  • Strategic assessments of therapeutic indications, including competition from current therapies, market opportunities, and novel drug targets
  • The design of screening strategies with key ”Go/No Go” decision points
  • Long-term collaborations bringing our expertise into our clients’ research projects to facilitate and expedite the discovery and selection of drug candidates for clinical development
  • The guidance, design and management of non-clinical efficacy and safety testing to differentiate clients’ drug-candidates from the competitors
  • Early-stage abuse and dependence liability assessments to de-risk programs
  • Ensuring FDA and EMA compliance for the design and conduct of studies

Our Expertise

DevelRx’s consultants each has at least 30 years of experience in R&D, managing programs at Boots Pharmaceuticals, Knoll Pharmaceuticals (BASF Pharma), and in RenaSci with a range of external biotech and pharmaceutical industry clients. We have initiated clinical development of drug-candidates and supported successful development and registration of 16 new drugs for the treatment of opiate withdrawal, ADHD, binge-eating disorder, schizophrenia, opiate-induced constipation, Parkinson’s disease, epilepsy, anaesthesia, obesity and type 2 diabetes. As globally acknowledged experts in evaluating drug abuse risks, we provide a key service in de-risking early-stage projects in therapeutic indications where regulatory approval and controlled drug scheduling are major obstacles to commercial viability.

Therapeutic Areas

  • Treatments for substance use disorders
  • Pain
  • Anaesthetics
  • ADHD
  • Epilepsy
  • Anxiety
  • Depression
  • Schizophrenia
  • Binge-eating disorder
  • Parkinson’s disease
  • Alzheimer’s disease
  • Obesity
  • Type 2 diabetes


  • Drug Development
  • Registration
  • Marketing

Get in touch to find out how we can help you.